ClinicalTrials.gg
Active, not recruitingNCT04644770Updated Nov 3, 2026

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

A Phase 1 interventional study of JNJ-69086420 and JNJ-78278343 in Prostatic Neoplasms and Adenocarcinoma, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 11 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
144
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 88 studies in Prostatic Neoplasms by Johnson & Johnson — 9 open to participants now, 23 under way, 9 of them phase 3. Prostatic Neoplasms · Johnson & Johnson.

Enrollment
24th of 68
144 · median 82
Started
2020
with 6 others
Phase 1
27 of 88
5 open now
Primary completion
2026-12
later than 8 of 22 live
Registered
71st of 88
by date

Among the 88 studies in Prostatic Neoplasms by Johnson & Johnson, this one is the 24th largest by enrollment of the 68 interventional ones that give a count, is one of 7 that started in 2020, is one of 27 in phase 1, reaches primary completion later than 8 of the 22 other live ones, and was the 71st registered.

Prostatic Neoplasms

7,053 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 88 studies in Prostatic Neoplasms by Johnson & Johnson are open now, in 8 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 1,233 Prostatic Neoplasms studies recruiting now, 931 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Prostatic Neoplasms by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of JNJ-69086420 in Part 1 (Dose Escalation), to determine safety and preliminary signs of clinical activity at the RP2D(s) in Part 2 (Dose Expansion), to determine safety of JNJ-69086420 at the RP2D(s) as a combination therapy in Part 3 (combination therapy) and to determine safety of JNJ-69086420 at the RP2D(s) in participants with metastatic hormone-sensitive prostate cancer (mHSPC) in Part 4.

03

Conditions studied

  • Prostatic Neoplasms
  • Adenocarcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For Part 1, Part 2, Part 3: castration resistant prostate cancer (mCRPC) with histologic confirmation of adenocarcinoma (adenocarcinoma with small-cell or neuroendocrine features is allowed) with prior exposure to at least one androgen receptor (AR) targeted therapy (for example [e.g.], abiraterone acetate, enzalutamide, apalutamide, darolutamide). In addition: Part 1: prior taxane or other chemotherapy is acceptable but not required. Part 2a: prior taxane or other chemotherapy required, Part 2b: no prior taxane or other chemotherapy, Part 2c: mCRPC that has progressed after prior treatment with lutetium Lu-177 vipivotide tetraxetan, with or without prior chemotherapy, Part 3: prior taxane or other chemotherapy is acceptable but not required \& For Part 4a: metastatic HSPC, For Part 4b: disease that can be treated with less than or equal to (\<=) 5 radiation fields and no visceral metastases
  • Parts 1, 2 \& 3: Prior orchiectomy or medical castration, or, for participants who have not undergone orchiectomy, must be receiving ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analog (agonist or antagonist) prior to the first dose of study drug and must continue this therapy throughout the treatment phase. This criterion does not apply to Part 4
  • Palliative radiotherapy (e.g. soft tissue lesions) must be completed greater than (>) 2 weeks prior to start of study drug except for palliative radiotherapy for pain (e.g., bone pain), which may be used any time prior to first dose
  • (ECOG) performance status of 0 or 1
  • Adequate organ functions as reflected in laboratory parameters

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with radium Xofigo (Ra 223 dichloride), strontium, samarium, or other radioconjugate therapy, other systemic anti-neoplastic therapy \<=30 days prior to the first dose of study drug except for luteinizing hormone-releasing hormone agonists/antagonists or GnRH agonists/antagonists. Novel androgen axis drugs \<=14 days prior to the first dose of study drug. In addition: Part 2b: Must not have received prior treatment with chemotherapy (eg, docetaxel) or poly ADP ribose polymerase (PARP) inhibitors, Part 2c: Prior treatment with lutetium Lu-177 vipivotide tetraxetan is required, but must have been completed >42 days prior to first dose of study drug, Part 3: Must not have received prior treatment with JNJ-78278343, Part 4: Must not have received ADT or AR-targeted therapy less than or equal to (\<=) 56 days prior to first dose of study drug
  • Known history of myelodysplastic syndrome, leukemia, or hematological with features suggestive of myelodysplastic syndrome/acute myeloid leukemia at any timepoint
  • Toxicity from prior anticancer therapy has not resolved to baseline levels or to Grade \<= 1 (except alopecia, radiation tissue fibrosis, or peripheral neuropathy)
  • Known allergies, , or intolerance to JNJ-69086420 or its and protein therapeutics. For Part 3, known allergies, hypersensitivity, or intolerance to JNJ-78278343 or its excipients or protein therapeutics
  • Active or chronic or infection
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
144 participants (actual)

Study arms

  • Experimental
    Part 1: Dose Escalation

    Participants will receive JNJ-69086420 with one or multiple doses. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.

    Drug: JNJ-69086420

  • Experimental
    Part 2: Dose Expansion

    Participants in one or more cohorts will receive JNJ-69086420 at the RP2D(s) determined in Part 1.

    Drug: JNJ-69086420

  • Experimental
    Part 3: Combination Therapy

    Participants will receive JNJ-69086420 at the determined RP2D(s) and fixed dose of JNJ-78278343.

    Drug: JNJ-69086420 · Drug: JNJ-78278343

  • Experimental
    Part 4: HSPC Expansion

    Participants with HSPC will receive JNJ-69086420 at the RP2D(s) in Part 4(a), and JNJ-69086420 following stereotactic body radiation therapy in Part 4(b).

    Drug: JNJ-69086420 · Radiation: Stereotactic body radiation therapy

Interventions

  • DrugJNJ-69086420

    Participants will receive JNJ-69086420.

    Also known as: Actinium-225-DOTA-h11B6

  • Participants will receive JNJ-78278343.

  • RadiationStereotactic body radiation therapy

    Participants will receive stereotactic body radiaition therapy.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability

    An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

    Time frame: Up to 2 years and 4 months

  2. Part 1: Number of Participants with Dose-Limiting Toxicity (DLT)

    Number of participants with DLT will be assessed. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity.

    Time frame: Up to 2 years and 4 months

  3. Number of Participants with AEs by Severity

    Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.

    Time frame: Up to 2 years and 4 months

Secondary outcomes

  1. Percentage of Participants with Prostate Specific Antigen (PSA) Response

    PSA response rate is defined as the percentage of participants with a decline of PSA of 50 percent (%) or more from baseline and that is subsequently confirmed.

    Time frame: Up to 2 years and 4 months

  2. Overall Response Rate (ORR)

    ORR is defined as the percentage of participants who have a Partial Response (PR) or better according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 without evidence of bone progression according to Prostate Cancer Working Group 3 (PCWG3).

    Time frame: Up to 2 years and 4 months

  3. Maximum Observed Serum Concentration/Radioactivity (Cmax) of JNJ-69086420

    Cmax is defined as the maximum observed serum concentration/radioactivity of JNJ-69086420.

    Time frame: Up to 2 years and 4 months

  4. Time to Reach Maximum Observed Serum Concentration/Radioactivity (Tmax) of JNJ-69086420

    Tmax is defined as time to reach maximum observed serum concentration/radioactivity of JNJ-69086420.

    Time frame: Up to 2 years and 4 months

  5. Area Under the Serum Concentration-time Curve From Time Zero to t Time (AUC[0-t]) of JNJ-69086420

    AUC(0-t) is defined as the area under the serum concentration-time curve from time zero to t of JNJ-69086420.

    Time frame: Up to 2 years and 4 months

  6. Number of Participants With Anti-JNJ-69086420 Antibodies

    Number of participants with anti-JNJ-69086420 antibodies will be assessed to evaluate the potential immunogenicity.

    Time frame: Up to 2 years and 4 months

  7. Part 3: Serum Concentration of JNJ-78278343

    Venous blood samples will be collected for assessment of serum concentrations of JNJ-78278343.

    Time frame: Up to 2 years and 4 months

  8. Part 3:Number of Participants With Anti-JNJ-78278343 Antibodies

    Number of participants with anti-JNJ-78278343 antibodies will be assessed to evaluate the potential immunogenicity.

    Time frame: Up to 2 years and 4 months

07

Study locations

11 sites
08

References and documents

Publications

  • Lehner F, Salemi S, Millan C, Kundig C, Eberli D. Inhibition of Growth and Induction of Apoptosis of Human Prostate Cancer Cells by Enzymatic Blockage of Kallikreins. Prostate Cancer. 2026 Jan 11;2026:7871208. doi: 10.1155/proc/7871208. eCollection 2026. PubMed 41531507 ↗

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · innovativemedicine.jnj.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Dec 2026, 72 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 62. This study's planned 72 months is above that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2020
First posted
Nov 25, 2020
StartActual
Nov 12, 2020
Primary completionEst.
Dec 8, 2026
CompletionEst.
Dec 30, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
2 updates, last Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    Minor edits only
    + 1 other change: verification date
  2. Sep 28, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04644770
Responsible party
Sponsor
First posted
Nov 25, 2020
Start date
Nov 12, 2020
Primary completion
Dec 8, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Nov 3, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion